Compound ID | 519

Update compound information

Fosmidomycin (FR 31564)

Class: DXP reductoisomerase inhibitor (phosphonic acid derivative)

Spectrum of activity: Gram-positive
Details of activity: Targets the cell wall; effective against Pseudomonas aeruginosa and E. coli.
Institute where first reported: Vicuron Pharmaceuticals (Pfizer, USA)
Highest developmental phase: Phase 2
Development status: Inactive
Reason Dropped: Development of resistance due to access into cells through glycerophosphate transporter
Chemical structure(s):
Click here for structure editor
Molecular weight: 183.1
Iso. SMILES: C(CN(C=O)O)CP(=O)(O)O
InChI Key: GJXWDTUCERCKIX-UHFFFAOYSA-N
Can. SMILES: C(CN(C=O)O)CP(=O)(O)O
InChI: InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/572
Guide to Pharmacology: fosmidomycin
Citation:

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.